SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 1, 2000
Biotech HOLDRsSM Trust
Initial Depositor
(Exact name of registrant as specified in its charter)
Biotech HOLDRsSM Trust
[Issuer with respect to the receipts]
New York
(State or other jurisdiction of incorporation)
Commission File Number
Not applicable
(I.R.S. Employer Identification No.)
c/o The Bank of New York, as Trustee
101 Barclay Street, 22-W
New York, New York
(Address of principal executive offices and zip code)
Page 1 of 5 pages.
The Exhibit Index appears at Page 4.
<PAGE>
Item 5. Other Events
Immunex Corporation has declared a three-for-one stock split on its
common stock, to be effected by means of a stock dividend to shareholders of
record on March 6, 2000. The shares of common stock will begin trading on a
split-adjusted basis on March 21, 2000. At such date, the share amount of
Immunex Corporation represented by a round-lot of 100 Biotech HOLDRs will be 42.
MedImmune, Inc. has declared a three-for-one stock split on its common
stock, to be effected by means of a stock dividend to shareholders of record on
May 18, 2000. The shares of common stock will begin trading on a split-adjusted
basis on June 5, 2000. At such date, the share amount of MedImmune, Inc.
represented by a round-lot of 100 Biotech HOLDRs will be 15.
Sepracor Inc. declared a two-for-one stock split on its common stock,
to be effected by means of a stock dividend to shareholders of record on
February 1, 2000. The shares of common stock began trading on a split-adjusted
basis on February 28, 2000. The share amount of Sepracor Inc. represented by a
round-lot of 100 Biotech HOLDRs is 6.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
(99) Biotech HOLDRsSM Trust Prospectus Supplement No. 2 dated
March 2, 2000 to Prospectus dated November 22, 1999.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED
Date: March 3, 2000 By: /s/ Stephen G. Bodurtha
---------------------------
Name: Stephen G. Bodurtha
Title: Attorney-in-Fact
3
<PAGE>
EXHIBIT INDEX
Number and Description of Exhibit Sequential
- --------------------------------- Page Number
-----------
(99) Biotech HOLDRsSM Trust Prospectus Pg. 5
Supplement No. 2 dated March 2, 2000 to
Prospectus dated November 22, 1999.
4
PROSPECTUS SUPPLEMENT No. 2
- ----------------------------
(To Prospectus dated November 22, 1999)
[GRAPHIC OMITTED]
1,000,000,000 Depositary Receipts
Biotech HOLDRsSM Trust
This prospectus supplement amends and supplements certain information contained
in the accompanying prospectus dated November 22, 1999 relating to the sale of
up to 1,000,000,000 depositary receipts by Biotech HOLDRsSM Trust.
The share amounts specified in the table on page 9 of the accompanying
prospectus shall be replaced with the following:
<TABLE>
<CAPTION>
Primary
Trading
Name of Company Ticker Share Amounts Market
--------------- ------ ------------- -------
<S> <C> <C> <C>
Amgen Inc. AMGN 46 NASDAQ
Genentech, Inc. DNA 22 NYSE
Biogen, Inc. BGEN 13 NASDAQ
Immunex Corporation(1) IMNX 14 NASDAQ
PE Corp-PE Biosystems Group PEB 18* NYSE
MedImmune, Inc.(2) MEDI 5 NASDAQ
Chiron Corporation CHIR 16 NASDAQ
Genzyme Corporation GENZ 7 NASDAQ
Gilead Sciences, Inc. GILD 4 NASDAQ
Sepracor Inc. SEPR 6* NASDAQ
IDEC Pharmaceuticals Corporation IDPH 4* NASDAQ
QLT Photo Therapeutics Inc. QLTI 5 NASDAQ
Millennium Pharmaceuticals, Inc. (3) MLNM 3 NASDAQ
BioChem Pharma Inc. BCHE 9 NASDAQ
Affymetrix, Inc. AFFX 2 NASDAQ
Human Genome Sciences, Inc. HGSI 4* NASDAQ
ICOS Corporation ICOS 4 NASDAQ
Enzon, Inc. ENZN 3 NASDAQ
Celera Genomics CRA 4* NYSE
Alkermes, Inc. ALKS 2 NASDAQ
</TABLE>
- ----------
* Reflects adjustment for previous stock split.
(1) Immunex Corporation has declared a three-for-one stock split on its common
stock, to be effected by means of a stock dividend to shareholders of
record as of March 6, 2000. The shares of common stock will begin trading
on a split-adjusted basis on March 21, 2000. At such date, the share amount
of Immunex Corporation represented by a round-lot of 100 Biotech HOLDRs
will be 42.
(2) MedImmune, Inc. has declared a three-for-one stock split on its common
stock, to be effected by means of a stock dividend to shareholders of
record as of May 18, 2000. The shares of common stock will begin trading on
a split-adjusted basis on June 5, 2000. At such date, the share amount of
MedImmune, Inc. represented by a round-lot of 100 Biotech HOLDRs will be
15.
(3) Millennium Pharmaceuticals, Inc. declared a two-for-one stock split on its
common stock, to be effected by means of a stock dividend to shareholders
of record on March 28, 2000. The shares of common stock will begin trading
on a split-adjusted basis on April 19, 2000. At such date, the share amount
of Millenium Pharmaceuticals, Inc. represented by a round-lot of 100
Biotech HOLDRs will be 6.
The stock prices in the tables set forth in Annex A of the accompanying
prospectus have not been and will not be, adjusted to account for any stock
splits.
The date of this prospectus supplement is March 2, 2000.
